Literature DB >> 23128153

State-dependent changes in hippocampal grey matter in depression.

D Arnone1, S McKie, R Elliott, G Juhasz, E J Thomas, D Downey, S Williams, J F W Deakin, I M Anderson.   

Abstract

Reduced hippocampal volume has been reported in depression and may be involved in the aetiology of depressive symptoms and vulnerability to depressive relapse. Neuroplasticity following antidepressant drug treatment in the hippocampus has been demonstrated in animal models but adaptive changes after such treatment have not been shown in humans. In this study, we determined whether grey matter loss in the hippocampus in depression (1) is present in medication-free depressed (2) changes in response to antidepressant treatment and (3) is present as a stable trait in medication-free remitted patients. Sixty-four medication-free unipolar depressed patients: 39 currently depressed and 25 in remission, and 66 healthy controls (HC) underwent structural magnetic resonance imaging in a cross-sectional and longitudinal design. Thirty-two currently depressed participants were then treated with the antidepressant citalopram for 8 weeks. Adherence to treatment was evaluated by measuring plasma citalopram concentration. We measured regional variation in grey matter concentration by using voxel-based morphometry-Diffeomorphic Anatomical Registration Through Exponentiated Lie algebra. Patients with current depression had bilaterally reduced grey matter in the hippocampus compared with HC and untreated patients in stable remission with the latter groups not differing. An increase in grey matter was observed in the hippocampus following treatment with citalopram in currently depressed patients. Grey matter reduction in the hippocampus appears specific to the depressed state and is a potential biomarker for a depressive episode.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23128153     DOI: 10.1038/mp.2012.150

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  92 in total

1.  Ablation of Type III Adenylyl Cyclase in Mice Causes Reduced Neuronal Activity, Altered Sleep Pattern, and Depression-like Phenotypes.

Authors:  Xuanmao Chen; Jie Luo; Yihua Leng; Yimei Yang; Larry S Zweifel; Richard D Palmiter; Daniel R Storm
Journal:  Biol Psychiatry       Date:  2015-12-19       Impact factor: 13.382

2.  Morphometry of the Hippocampus Across the Adult Life-Span in Patients with Depressive Disorders: Association with Neuroticism.

Authors:  Yu Liu; Jie Meng; Kangcheng Wang; Kaixiang Zhuang; Qunlin Chen; Wenjing Yang; Jiang Qiu; Dongtao Wei
Journal:  Brain Topogr       Date:  2021-05-14       Impact factor: 3.020

3.  White Matter Tract Integrity, Involvement in Sports, and Depressive Symptoms in Children.

Authors:  Lisa S Gorham; Deanna M Barch
Journal:  Child Psychiatry Hum Dev       Date:  2020-01-25

4.  Stem Cell Factor (SCF) is a putative biomarker of antidepressant response.

Authors:  Francesco Benedetti; Sara Poletti; Thomas A Hoogenboezem; Clara Locatelli; Oliver Ambrée; Harm de Wit; Annemarie J M Wijkhuijs; Elena Mazza; Chiara Bulgarelli; Benedetta Vai; Cristina Colombo; Enrico Smeraldi; Volker Arolt; Hemmo A Drexhage
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-23       Impact factor: 4.147

5.  The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder.

Authors:  Li Wang; Mingrui Xia; Ke Li; Yawei Zeng; Yunai Su; Wenji Dai; Qinge Zhang; Zhen Jin; Philip B Mitchell; Xin Yu; Yong He; Tianmei Si
Journal:  Hum Brain Mapp       Date:  2014-10-21       Impact factor: 5.038

6.  Volumetric brain differences in clinical depression in association with anxiety: a systematic review with meta-analysis.

Authors:  Daniela A Espinoza Oyarce; Marnie E Shaw; Khawlah Alateeq; Nicolas Cherbuin
Journal:  J Psychiatry Neurosci       Date:  2020-11-01       Impact factor: 6.186

7.  Social anhedonia in major depressive disorder: a symptom-specific neuroimaging approach.

Authors:  Verena Enneking; Pia Krüssel; Dario Zaremba; Katharina Dohm; Dominik Grotegerd; Katharina Förster; Susanne Meinert; Christian Bürger; Fanni Dzvonyar; Elisabeth J Leehr; Joscha Böhnlein; Jonathan Repple; Nils Opel; Nils R Winter; Tim Hahn; Ronny Redlich; Udo Dannlowski
Journal:  Neuropsychopharmacology       Date:  2018-11-27       Impact factor: 7.853

8.  Multimodal imaging of a tescalcin (TESC)-regulating polymorphism (rs7294919)-specific effects on hippocampal gray matter structure.

Authors:  U Dannlowski; H J Grabe; K Wittfeld; J Klaus; C Konrad; D Grotegerd; R Redlich; T Suslow; N Opel; P Ohrmann; J Bauer; P Zwanzger; I Laeger; C Hohoff; V Arolt; W Heindel; M Deppe; K Domschke; K Hegenscheid; H Völzke; D Stacey; H Meyer Zu Schwabedissen; H Kugel; B T Baune
Journal:  Mol Psychiatry       Date:  2014-04-29       Impact factor: 15.992

9.  Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E.

Authors:  Shanna L Burke; Peter Maramaldi; Tamara Cadet; Walter Kukull
Journal:  Int J Geriatr Psychiatry       Date:  2017-05-31       Impact factor: 3.485

Review 10.  Structural and functional neuroimaging studies in major depressive disorder with psychotic features: a critical review.

Authors:  Geraldo F Busatto
Journal:  Schizophr Bull       Date:  2013-04-24       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.